CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


pathogen reduced SARS-CoV-2 convalescent plasmaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1973 Quantitative analysis of anti-SARS-CoV-2-antibodies Wiki 1.00
drug2136 SARS-CoV-2 diagnostic rapid test Wiki 0.71
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Randomized, Controlled Clinical Trial to Test the Safety and Efficacy of Convalescent Donor Plasma to Treat COVID-19 in Hospitalized Adults

The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting. The effect of convalescent plasma will be compared to placebo on clinical outcomes, measured using the COVID Ordinal Outcomes Scale at Day 15, among adults with COVID-19 requiring hospitalization.

NCT04362176 COVID-19 Coronavirus SARS-CoV-2 Biological: pathogen reduced SARS-CoV-2 convalescent plasma Biological: Placebo
MeSH:Coronavirus Infections

Primary Outcomes

Description: Death Hospitalized on invasive mechanical ventilation or ECMO Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)

Measure: COVID Ordinal Outcomes Scale:Day 15

Time: Study Day 15

Secondary Outcomes

Description: All-location, all-cause 14-day mortality

Measure: All-location, all-cause 14-day mortality

Time: Baseline to Study Day 14

Description: All-location, all-cause 28-day mortality

Measure: All-location, all-cause 28-day mortality

Time: Baseline to Study Day 28

Description: Death Hospitalized on invasive mechanical ventilation or ECMO Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)

Measure: COVID Ordinal Outcomes Scale Day 3

Time: Baseline to Study Day 3

Description: Death Hospitalized on invasive mechanical ventilation or ECMO Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)

Measure: COVID Ordinal Outcomes Scale Day 8

Time: Study Day 8

Description: Death Hospitalized on invasive mechanical ventilation or ECMO Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)

Measure: COVID Ordinal Outcomes Scale Day 29

Time: Study Day 29

Description: Number of participants that died or received ECMO

Measure: Composite of death or receipt of ECMO through Day 28

Time: Baseline to Day 28

Description: Number of days without use of oxygen

Measure: Oxygen-free days through Day 28

Time: Baseline to Day 28

Description: Number of days without use of vasopressors

Measure: Vasopressor-free days through Day 28

Time: Baseline to Day 28

Description: Number of days without use of a ventilator

Measure: Ventilator-free days through Day 28

Time: Baseline to Day 28

Description: Number of days outside of ICU

Measure: ICU-free days through Day 28

Time: Baseline to Day 28

Description: Number of days outside of the hospital

Measure: Hospital-free days through Day 28

Time: Baseline to Day 28

Other Outcomes

Description: Number of participants with Acute kidney injury

Measure: Acute kidney injury

Time: Baseline to Day 28

Description: Number of participants requiring renal replacement therapy

Measure: Renal replacement therapy

Time: Baseline to Day 28

Description: Number of participants with documented venous thromboembolic disease (DVT or PE)

Measure: Documented venous thromboembolic disease (DVT or PE)

Time: Baseline to Day 28

Description: Number of Participants with myocardial infarction or ischemic stroke

Measure: Documented cardiovascular event (myocardial infarction or ischemic stroke)

Time: Baseline to Day 28

Description: Number of participants with transfusion reaction (fever/rash)

Measure: Transfusion reaction

Time: Baseline to Day 28

Description: Number of participants with transfusion related acute lung injury (TRALI)

Measure: Transfusion related acute lung injury (TRALI)

Time: Baseline to Day 28

Description: Number of participants with transfusion associated circulatory overload (TACO)

Measure: Transfusion associated circulatory overload (TACO)

Time: Baseline to Day 28

Description: Number of participants with transfusion related infection

Measure: Transfusion related infection

Time: Baseline to Day 28


No related HPO nodes (Using clinical trials)